SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. - Wikidata - wikimedia - TriplyDB

SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.

SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.

http://www.wikidata.org/entity/Q33431098

about

Proteomics in molecular diagnosis: typing of amyloidosis Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.Biomarker discovery and clinical proteomics.Age-dependent increase in thiol conjugated forms of transthyretin (TTR) in the elderly: quantitative analyses by the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) protein chip system.The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry.Ovine serum biomarkers of early and late phase scrapie.Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles.Recent advances in transthyretin amyloidosis therapy Derivatization strategies for CE-LIF analysis of biomarkers: Toward a clinical diagnostic of familial transthyretin amyloidosis.Rapid detection of wild-type and mutated transthyretins.Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.Clinical proteomics for diagnosis and typing of systemic amyloidoses.Diagnosis of familial amyloid polyneuropathy: wide-ranged clinicopathological features.Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts.Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype.Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease.Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.Dominant cardiac type of familial amyloidotic polyneuropathy associated with a novel transthyretin variant Thr59Arg.Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study.Systemic amyloidoses and proteomics: The state of the art.Abstracts How proteomic ApoE serotyping could impact Alzheimer’s disease risk assessment: genetic testing by proteomics Transthyretin-derived amyloidosis in musculoskeletal systems Knee osteoarthritis associated with different kinds of amyloid deposits and the impact of aging on type of amyloid Two brothers homozygous for the TTR V30M both presenting with a phenotype dominated by central nervous complications Spinal multifocal amyloidosis derived from wild-type transthyretin

P2860

Q26823596-9CE4533E-106B-4555-912D-564125C89DE6 Q33520447-CB06B814-18D5-48D0-B09C-A4481F5FC475 Q33655101-0C0D2FDD-506E-4214-AA4A-97C7C103C823 Q33991820-96F67342-1898-45F2-873C-93ABBA8D12CC Q34073701-D5066A01-C33F-45BC-8D38-D3B8133D51AD Q34332056-FAB1E6C7-A943-4372-8892-A9F4CE241D7D Q34490823-F7151E67-C6D0-4285-A2F9-3406428EDC56 Q34664696-D529B2B9-B3D3-414B-8AFD-EACEEF5E5BF0 Q35047273-8702CEA9-D500-49FA-910A-9276DB00F3E1 Q35765201-71DF3050-09A4-469D-A744-97AF3BC01F5B Q36142761-5DF1ABE4-28C6-4350-ACE0-BC8B77294F6D Q37778217-45C59C8C-34BE-48A1-930E-FEB32C9ED8FC Q38062901-68D41717-3A54-4335-B102-54B308279C4D Q38089871-B81314F8-992A-4418-B3B1-20BBDF3D198C Q39396200-C1734BCA-F451-48F6-98FF-C4CB5FFF8826 Q40607990-82266443-1479-4BAA-BD66-31AE6315F424 Q45899656-CD7309AB-6D49-4421-9563-AD0A1EE0F9F2 Q47206219-02D59277-CCED-4A44-89DA-FC6E04B40A86 Q47561760-35F311F3-B370-4403-B743-B9A23C685723 Q50850791-79B7166C-C7CD-42B4-B852-A49612308C03 Q51016842-7C3282CF-9AA0-47AC-B9E1-16934258E6DC Q55167558-08419B67-6A26-4F31-BE06-58D389238038 Q57259399-2A9AAEF2-62EE-4C95-916C-8B377E2E3E6A Q57707722-5331130D-0D82-4B81-A754-30ED88D7BF90 Q58124993-116CB2F7-2427-43DD-BFC4-855994E8558B Q58248637-B389D955-42AB-43BB-9A88-9A3724FE56FE Q58266998-A4812AC7-FC52-4891-AF99-DA71BCA032FB Q58267198-3467E9E3-F330-456D-BBBA-B87B61DB3DCC

P2860

SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.

http://www.wikidata.org/entity/Q33431098

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

SELDI-TOF mass spectrometry ev ...... al amyloidotic polyneuropathy.

@ast

SELDI-TOF mass spectrometry ev ...... al amyloidotic polyneuropathy.

@en

type

label

SELDI-TOF mass spectrometry ev ...... al amyloidotic polyneuropathy.

@ast

SELDI-TOF mass spectrometry ev ...... al amyloidotic polyneuropathy.

@en

prefLabel

SELDI-TOF mass spectrometry ev ...... al amyloidotic polyneuropathy.

@ast

SELDI-TOF mass spectrometry ev ...... al amyloidotic polyneuropathy.

@en

P1433

Q33431098-3AD210BC-8CB0-4A34-A4D0-86DD50028639

P1476

Q33431098-45CADEF2-1497-43B1-9111-6BC6E4298AFE

P2093

Q33431098-12E184D7-7992-4291-8861-DF941C916E24

Q33431098-2C63309A-FC56-44B6-9652-0426559DE98E

Q33431098-3988C85A-14EB-4991-A348-A62AF11BAB04

Q33431098-499FF76F-DDF0-4291-B18E-BFEDEDAEF91A

Q33431098-5FF0CFCF-AFC0-4C3A-9052-399264CF194E

Q33431098-8F5E2101-FA5F-4DBD-A445-4BFE3DC089EF

Q33431098-95C6A699-91F7-4368-9096-63A22DDB39A0

Q33431098-CEADD193-60EC-4D01-854B-0FE939C9ACFC

Q33431098-DB865343-E09E-4C07-8021-FEB449C4D8F6

Q33431098-E1EA6D54-47E9-4667-B59D-AEA7E74CA954

P304

Q33431098-7E78ED20-B3FB-48B0-A788-BBB246DC9482

P31

Q33431098-0FEE4C70-DAAF-4B6E-B00D-41FF4851B014

P356

Q33431098-7E63A0F7-8C33-421E-B752-34A1C4A82CF8

P407

Q33431098-0EB21FAB-4312-4307-A49F-5A96771EEEA2

P433

Q33431098-979632C0-B8B7-41B1-9EAD-D3DA231F0EED

P478

Q33431098-8ED4BD6A-5174-4D2B-AAF2-2B227CFAB36F

P50

Q33431098-7D9A94C8-E8B0-4436-A1D5-C025412225B9

P577

Q33431098-B4723EF6-BD1C-4F21-AAFB-CEA58706C805

P5875

Q33431098-7FD8BC4C-CB16-4778-92A7-7FA35BB85199

P698

Q33431098-B7592B0B-A2C6-43E5-B697-07A950ECC704

P356

CLINCHEM.2008.118505

P1433

Clinical Chemistry

P1476

SELDI-TOF mass spectrometry ev ...... ial amyloidotic polyneuropathy

@en

P2093

Hirofumi Jono

http://www.w3.org/2001/XMLSchema#string

Kazutoshi Ota

http://www.w3.org/2001/XMLSchema#string

Masaaki Nakamura

http://www.w3.org/2001/XMLSchema#string

Mineyuki Mizuguchi

http://www.w3.org/2001/XMLSchema#string

Mitsuharu Ueda

http://www.w3.org/2001/XMLSchema#string

Satoru Shinriki

http://www.w3.org/2001/XMLSchema#string

Shu-ichi Ikeda

http://www.w3.org/2001/XMLSchema#string

Taro Yamashita

http://www.w3.org/2001/XMLSchema#string

Yohei Misumi

http://www.w3.org/2001/XMLSchema#string

Yoshiki Sekijima

http://www.w3.org/2001/XMLSchema#string

P304

1223-1227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1373/CLINCHEM.2008.118505

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24283052

http://www.w3.org/2001/XMLSchema#string

P698

19372189

http://www.w3.org/2001/XMLSchema#string